Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Az A és C csoportú meningococcus poliszacharid vakcina III. fázisú klinikai vizsgálata

Véletlenszerű, kettős vak, ellenőrzött, nem inferioritás III. fázisú kísérlet egy A és C csoportú meningococcus poliszacharid vakcinával 2-6 éves egészséges gyermekeken

This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A and C meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 2-6 years.

A tanulmány áttekintése

Részletes leírás

This study was divided into two stages. The first stage study was an early safety assessment study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged 18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200 healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal vaccine after immunization.

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

1280

Fázis

  • 3. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

    • Yunnan
      • Kunming, Yunnan, Kína
        • Yunnan Center for Disease Control and Prevention

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

2 év (Gyermek, Felnőtt)

Egészséges önkénteseket fogad

Igen

Tanulmányozható nemek

Összes

Leírás

  • The First stage study (An early safety assessment study):

  • 18-50 years group:

    • Inclusion Criteria:

      1. Healthy adults aged 18 to 50 years.
      2. Proven legal identity.
      3. Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
      4. Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
      5. Axillary temperature ≤37.0℃.
    • Exclusion Criteria:

      1. Contraindications for vaccination.
      2. History of allergy to vaccines or drugs.
      3. History of Epidemic Cerebrospinal Meningitis.
      4. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
      5. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
      6. Immunization with any vaccine within 30 days.
      7. Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
      8. History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors.
      9. Those who developed acute disease or acute attack of chronic disease.
      10. Surgical removal of spleen or other important organs for any reason.
      11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
      12. Blood products such as immunoglobulin were received within 30 days before vaccination.
      13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
      14. Those who participated in other clinical studies.
      15. Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination.
      16. Any other situations judged by investigators as not suitable for participating in this study.
  • 7-17 years group:

    • Inclusion Criteria

      1. Healthy volunteer aged 7 to 17 years.
      2. Proven legal identity.
      3. Participants and their legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
      4. Participants and their legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
      5. Axillary temperature ≤37.0℃.
    • Exclusion Criteria:

      1. Contraindications for vaccination.
      2. History of allergy to vaccines or drugs.
      3. History of Epidemic Cerebrospinal Meningitis.
      4. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
      5. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
      6. Immunization with any vaccine within 30 days.
      7. Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
      8. Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
      9. Those who developed acute disease or acute attack of chronic disease.
      10. Surgical removal of spleen or other important organs for any reason.
      11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
      12. Blood products such as immunoglobulin were received within 30 days before vaccination.
      13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
      14. Those who participated in other clinical studies.
      15. Women with positive pregnancy test after menarche.
      16. Any other situations judged by investigators as not suitable for participating in this study.
  • 2-6 years group:

    • Inclusion Criteria

      1. Healthy children aged 2 to 6 years.
      2. Proven legal identity.
      3. Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
      4. Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
      5. Axillary temperature ≤37.0℃.
    • Exclusion Criteria:

      1. Contraindications for vaccination.
      2. History of allergy to vaccines or drugs.
      3. History of Epidemic Cerebrospinal Meningitis.
      4. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
      5. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
      6. They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
      7. Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
      8. Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
      9. Those who developed acute disease or acute attack of chronic disease.
      10. Surgical removal of spleen or other important organs for any reason.
      11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
      12. Blood products such as immunoglobulin were received within 30 days before vaccination.
      13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
      14. Those who participated in other clinical studies.
      15. Any other situations judged by investigators as not suitable for participating in this study.

The Second stage study (A phase III clinical trial )

  • Inclusion Criteria

    1. Healthy children aged 2 to 6 years.
    2. Proven legal identity.
    3. Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
    4. Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
    5. Axillary temperature ≤37.0℃.
  • Exclusion Criteria:

    1. Contraindications for vaccination.
    2. History of allergy to vaccines or drugs.
    3. History of Epidemic Cerebrospinal Meningitis.
    4. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
    5. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
    6. They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
    7. Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
    8. Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
    9. Those who developed acute disease or acute attack of chronic disease.
    10. Surgical removal of spleen or other important organs for any reason.
    11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
    12. Blood products such as immunoglobulin were received within 30 days before vaccination.
    13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
    14. Those who participated in other clinical studies.
    15. Any other situations judged by investigators as not suitable for participating in this study.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Megelőzés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Négyszeres

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Experimental Vaccine

One dose of Experimental Group A and C meningococcal polysaccharide vaccine

One dose of Experimental Group A and C meningococcal polysaccharide vaccine

Aktív összehasonlító: Active Comparator Vaccine

One dose of Control Group A and C meningococcal polysaccharide vaccine

One dose of Control Group A and C meningococcal polysaccharide vaccine

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Seroconversion rate of Group A meningococcal bactericidal antibody
Időkeret: 28 days after vaccination

Seroconversion rate of Group A meningococcal bactericidal antibody at day 28 after vaccination

28 days after vaccination
Seroconversion rate of Group C meningococcal bactericidal antibody
Időkeret: 28 days after vaccination

Seroconversion rate of Group C meningococcal bactericidal antibody at day 28 after vaccination

28 days after vaccination

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Adverse reactions/events rate
Időkeret: 7 days after vaccination

Occurence of adverse reactions/events after vaccination

7 days after vaccination
Adverse reactions/events rate
Időkeret: 28 days after vaccination

Occurence of adverse reactions/events after vaccination

28 days after vaccination
Serious adverse events
Időkeret: 6 months after the second vaccination

Occurence of Serious adverse events after vaccination

6 months after the second vaccination
GMT of Group A meningococcal bactericidal antibody
Időkeret: 28 days after the second vaccination

GMT of Group A meningococcal bactericidal antibody at day 28 after the second vaccination

28 days after the second vaccination
GMT of Group C meningococcal bactericidal antibody
Időkeret: 28 days after the second vaccination

GMT of Group C meningococcal bactericidal antibody at day 28 after the second vaccination

28 days after the second vaccination

Egyéb eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
GMT of IgG antibody against Hepatitis A
Időkeret: 28 days after the second vaccination

GMT of IgG antibody against Hepatitis A at day 28 after vaccination

28 days after the second vaccination
Seropositive rate of IgG antibody against Hepatitis A
Időkeret: 28 days after the second vaccination

Seropositive rate of IgG antibody against Hepatitis A at day 28 after vaccination

28 days after the second vaccination

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Nyomozók

  • Kutatásvezető: Yan Zheng, Mater, Yunnan Center for Disease Control and Prevention

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2020. szeptember 15.

Elsődleges befejezés (Tényleges)

2021. április 29.

A tanulmány befejezése (Tényleges)

2021. szeptember 26.

Tanulmányi regisztráció dátumai

Először benyújtva

2020. december 8.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2020. december 28.

Első közzététel (Tényleges)

2020. december 30.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. szeptember 29.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. szeptember 24.

Utolsó ellenőrzés

2026. szeptember 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

NEM

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel